Diagnostic potential of tumor DNA from ovarian cyst fluid

eLife

Volumn 5, Issue 2016JULY, 2016, Pages

  Wang, Yuxuan ^a,b   Sundfeldt, Karin ^c   Mateoiu, Constantina ^d   Shih, Ie Ming ^e   Kurman, Robert J ^e   Schaefer, Joy ^a,b   Silliman, Natalie ^a,b   Kinde, Isaac ^a,b   Springer, Simeon ^a,b   Foote, Michael ^a,b,f   Kristjansdottir, Björg ^c   James, Nathan ^a,b   Kinzler, Kenneth W ^a,b   Papadopoulos, Nickolas ^a,b   Diaz, Luis A ^a,b,f   Vogelstein, Bert ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f Ludwig Center for Cancer Genetics and Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CA 125 ANTIGEN; DNA; HUMAN EPIDIDYMIS PROTEIN 4; K RAS PROTEIN; MEMBRANE PROTEIN; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE 3 KINASE REGULATORY SUBUNIT 1; PROTEIN P53; PROTEIN PHOSPHATASE 2 SCAFFOLD SUBUNIT A ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; CYST FLUID; DNA ISOLATION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; OVARY CYST; PROTEIN PHOSPHORYLATION; VALIDATION PROCESS; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; GENETICS; OVARIAN CYSTS; OVARIAN NEOPLASMS; PATHOLOGY; PROSPECTIVE STUDY;

CYST FLUID; DIAGNOSIS, DIFFERENTIAL; DNA; FEMALE; HUMANS; MUTATION; OVARIAN CYSTS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84979544164     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.15175     Document Type: Article

References (62)

1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology G., Gynecologic Oncology Group. 2006. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine 354: 34-43. doi: 10.1056/NEJMoa052985
2. Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A. 2013. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clinical Chemistry and Laboratory Medicine 51: 1815-1824. doi: 10.1515/cclm-2013-0151
3. Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C. 2014. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid 24: 809-819. doi: 10.1089/thy.2013.0403
4. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine 309: 883-887. doi: 10.1056/ NEJM198310133091503
5. Beane JD, House MG, Coté GA, DeWitt JM, Al-Haddad M, LeBlanc JK, McHenry L, Sherman S, Schmidt CM, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD. 2011. Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. Surgery 150: 844-853. doi: 10.1016/j.surg.2011.07. 068
6. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, et al. 2014. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine 6: 224ra24. doi: 10.1126/scitranslmed.3007094
7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 20: 1248-1259. doi: 10.1200/JCO.20.5.1248
8. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, Team PP., PLCO Project Team. 2005. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology 193: 1630-1639. doi: 10.1016/j. ajog.2005.05.005
9. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, et al. 2011. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association 305: 2295-2303. doi: 10.1001/jama.2011.766
10. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi: 10.1038/nature10166
11. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. 1997. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointestinal Endoscopy 45: 387-393. doi: 10.1016/S0016-5107(97)70149-4
12. Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, Shih I. 2004. Molecular genetic analysis of ovarian serous cystadenomas. Laboratory Investigation 84: 778-784. doi: 10.1038/labinvest.3700103
13. Christensen JT, Boldsen JL, Westergaard JG. 2002. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 66: 153-157. doi: 10.1016/S0010-7824(02)00353-0
14. Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL. 2003. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Research 63: 5761-5766.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954. doi: 10.1038/nature00766
16. Demirol A, Guven S, Baykal C, Gurgan T. 2006. Effect of endometrioma cystectomy on IVF outcome: a prospective randomized study. Reproductive Biomedicine Online 12: 639-643. doi: 10.1016/S1472-6483(10) 61192-3
17. Duke D, Colville J, Keeling A, Broe D, Fotheringham T, Lee MJ. 2006. Transvaginal aspiration of ovarian cysts: long-term follow-up. Cardiovascular and Interventional Radiology 29: 401-405. doi: 10.1007/s00270-005-0167-0
18. Eloubeidi MA, Chen VK, Eltoum IA, Jhala D, Chhieng DC, Jhala N, Vickers SM, Wilcox CM. 2003. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. American Journal of Gastroenterology 98: 2663-2668. doi: 10. 1111/j.1572-0241.2003.08666.x
19. Frossard JL, Amouyal P, Amouyal G, Palazzo L, Amaris J, Soldan M, Giostra E, Spahr L, Hadengue A, Fabre M. 2003. Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. American Journal of Gastroenterology 98: 1516-1524. doi: 10.1111/j.1572-0241.2003.07530.x
20. Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S, Group DOS., DOvE Study Group. 2012. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet. Oncology 13: 285-291. doi: 10.1016/S1470-2045(11)70333-3
21. Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. 2013. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119: 548-554. doi: 10.1002/cncr.27782
22. Havrilesky LJ, Peterson BL, Dryden DK, Soper JT, Clarke-Pearson DL, Berchuck A. 2003. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstetrics and Gynecology 102: 243-251. doi: 10.1097/00006250-200308000-00008
23. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. 2003. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research 63: 3695-3700.
24. Hilger WS, Magrina JF, Magtibay PM. 2006. Laparoscopic management of the adnexal mass. Clinical Obstetrics and Gynecology 49: 535-548. doi: 10.1097/00003081-200609000-00013
25. Howlader N, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. 2014. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute.
26. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih I. 2012. Low-grade serous carcinomas of the ovary contain very few point mutations. Journal of Pathology 226: 413-420. doi: 10.1002/path.3967
27. Kim HS, Ahn JH, Chung HH, Kim JW, Park NH, Song YS, Lee HP, Kim YB. 2013. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. European Journal of Surgical Oncology 39: 279-289. doi: 10.1016/j.ejso.2012.12.003
28. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. 2011. Detection and quantification of rare mutations with massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America 108: 9530-9535. doi: 10.1073/pnas.1105422108
29. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih I, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA. 2013. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Science Translational Medicine 5: 167ra4. doi: 10.1126/scitranslmed.3004952
30. Kristjansdottir B, Levan K, Partheen K, Carlsohn E, Sundfeldt K. 2013. Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clinical Proteomics 10: 4. doi: 10.1186/1559-0275-10-4
31. Kudo T, Kawakami H, Kuwatani M, Eto K, Kawahata S, Abe Y, Onodera M, Ehira N, Yamato H, Haba S, Kawakubo K, Sakamoto N. 2014. Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. World Journal of Gastroenterology 20: 3620-3627. doi: 10.3748/wjg.v20.i13.3620
32. Kurman RJ, Shih I. 2010. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 34: 433-443. doi: 10.1097/PAS.0b013e3181cf3d79
33. Kurman RJ, Shih I. 2011. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Human Pathology 42: 918-931. doi: 10.1016/j.humpath.2011.03.003
34. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP. 2007. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Journal of Pathology 211: 26-35. doi: 10.1002/path.2091
35. Levine D, Brown DL, Andreotti RF, Benacerraf B, Benson CB, Brewster WR, Coleman B, Depriest P, Doubilet PM, Goldstein SR, Hamper UM, Hecht JL, Horrow M, Hur HC, Marnach M, Patel MD, Platt LD, Puscheck E, Smith-Bindman R. 2010. Management of asymptomatic ovarian and other adnexal cysts imaged at US: society of radiologists in ultrasound consensus conference statement. Radiology 256: 943-954. doi: 10.1148/radiol. 10100213
36. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. 2005. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 15: 708-717. doi: 10.1089/thy.2005.15.708
37. Loh FH, Tan AT, Kumar J, Ng SC. 1999. Ovarian response after laparoscopic ovarian cystectomy for endometriotic cysts in 132 monitored cycles. Fertility and Sterility 72: 316-321. doi: 10.1016/S0015-0282(99) 00207-1
38. Martínez-Onsurbe P, Ruiz Villaespesa A, Sanz Anquela JM, Valenzuela Ruiz PL. 2001. Aspiration cytology of 147 adnexal cysts with histologic correlation. Acta Cytologica 45: 941-947. doi: 10.1159/000328368
39. Mayr D, Hirschmann A, Löhrs U, Diebold J. 2006. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecologic Oncology 103: 883-887. doi: 10.1016/j.ygyno.2006.05.029
40. Moran O, Menczer J, Ben-Baruch G, Lipitz S, Goor E,. Lipitz S. Ben-Baruch S 1993. Cytologic examination of ovarian cyst fluid for the distinction between benign and malignant tumors. Obstetrics and Gynecology 82: 444-446.
41. Moyer VA, S. T. Force USP., U.S. Preventive Services Task Force. 2012. Screening for ovarian cancer: U.S. preventive services task force reaffirmation recommendation statement. Annals of Internal Medicine 157: 900-904. doi: 10.7326/0003-4819-157-11-201212040-00539
42. Mulvany NJ. 1996. Aspiration cytology of ovarian cysts and cystic neoplasms. A study of 235 aspirates. Acta Cytologica 40: 911-920. doi: 10.1159/000334002
43. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. 2013. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112. doi: 10. 1038/nature12065
44. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW, Alizadeh AA, Diehn M, Loo, Jr BW. 2014. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine 20: 548-554. doi: 10.1038/nm.3519
45. Ngamruengphong S, Xu C, Woodward TA, Raimondo M, Stauffer JA, Asbun HJ, Wallace MB. 2013. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needle aspiration. Endoscopy 45: 619-626. doi: 10.1055/s-0033-1344216
46. Ngamruengphong S, Swanson KM, Shah ND, Wallace MB. 2015. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. Gut 64 1105-1110. doi: 10.1136/gutjnl-2014-307475
47. Pavlik EJ, Ueland FR, Miller RW, Ubellacker JM, DeSimone CP, Elder J, Hoff J, Baldwin L, Kryscio RJ, van Nagell JR. 2013. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstetrics and Gynecology 122: 210-217. 2. doi: 10.1097/AOG.0b013e318298def5
48. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, Samuels Y, Velculescu VE, Vogelstein B, Kinzler KW, Diaz LA. 2007. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Research 67: 9364-9370. doi: 10.1158/0008-5472.CAN-07-0605
49. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. 2008. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology 108: 510-514. doi: 10.1016/j.ygyno.2007.11.013
50. Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, et al. 2012. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound in Obstetrics & Gynecology 40: 338-344. doi: 10.1002/uog.12270
51. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S. 2004. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100: 1045-1052. doi: 10. 1002/cncr.20080
52. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. 2011. Risk factors for recurrence of ovarian borderline tumors. Gynecologic Oncology 120: 480-484. doi: 10.1016/j.ygyno. 2010.11.016
53. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. 2015. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. Journal of Clinical Oncology 33: 1460-1466. doi: 10.1200/JCO. 2014.55.9898
54. Tran AA, Brown SB, Rosenberg J, Hovsepian DM. 2014. Tract embolization with gelatin sponge slurry for prevention of pneumothorax after percutaneous computed tomography-guided lung biopsy. Cardiovascular and Interventional Radiology 37: 1546-1553. doi: 10.1007/s00270-013-0823-8
55. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK. 2013. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Journal of Pathology 231: 449-456. doi: 10.1002/path.4252
56. Tsang WK, Luk WH, Lo A. 2014. Ultrasound-guided plugged percutaneous biopsy of solid organs in patients with bleeding tendencies. Hong Kong Medical Journal 20: 107-112. doi: 10.12809/hkmj133972
57. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z. 2011. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics and Gynecology 117: 1289-1297. doi: 10.1097/AOG.0b013e31821b5118
58. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558. doi: 10.1126/science.1235122
59. Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, Jewett MA. 2007. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. Journal of Urology 178: 379-386. doi: 10.1016/j.juro.2007.03.131
60. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, et al. 2011a. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America 108: 21188-21193. doi: 10.1073/pnas.1118046108
61. Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. 2011b. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Science Translational Medicine 3: 92ra66. doi: 10.1126/scitranslmed.3002543
62. Yamada R, Maeda N, Oguri H, Adachi Y, Takeuchi T, Furihata M, Fukaya T. 2013. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors? European Journal of Obstetrics, Gynecology, and Reproductive Biology 171: 96-100. doi: 10.1016/j.ejogrb.2013.08.003